ATE321755T1 - Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren - Google Patents

Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren

Info

Publication number
ATE321755T1
ATE321755T1 AT02722567T AT02722567T ATE321755T1 AT E321755 T1 ATE321755 T1 AT E321755T1 AT 02722567 T AT02722567 T AT 02722567T AT 02722567 T AT02722567 T AT 02722567T AT E321755 T1 ATE321755 T1 AT E321755T1
Authority
AT
Austria
Prior art keywords
aminoquinoline
producing
intermediate products
cetp inhibitors
cetp
Prior art date
Application number
AT02722567T
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE321755T1 publication Critical patent/ATE321755T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02722567T 2001-04-30 2002-04-08 Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren ATE321755T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ATE321755T1 true ATE321755T1 (de) 2006-04-15

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02722567T ATE321755T1 (de) 2001-04-30 2002-04-08 Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
AT02722569T ATE316957T1 (de) 2001-04-30 2002-04-08 Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02722569T ATE316957T1 (de) 2001-04-30 2002-04-08 Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate

Country Status (24)

Country Link
US (3) US6689897B2 (de)
EP (2) EP1425270B1 (de)
JP (2) JP3924250B2 (de)
KR (2) KR100639745B1 (de)
CN (3) CN100357265C (de)
AR (3) AR036331A1 (de)
AT (2) ATE321755T1 (de)
AU (1) AU2002253448B2 (de)
BR (2) BR0209238A (de)
CA (2) CA2445623A1 (de)
CZ (2) CZ20032900A3 (de)
DE (2) DE60209004T2 (de)
DK (2) DK1383734T3 (de)
ES (2) ES2259080T3 (de)
HU (2) HU225777B1 (de)
IL (2) IL157544A0 (de)
MX (2) MXPA03009936A (de)
PL (2) PL366700A1 (de)
PT (1) PT1425270E (de)
RU (2) RU2259355C2 (de)
TW (1) TWI250974B (de)
WO (2) WO2002088069A2 (de)
YU (2) YU84303A (de)
ZA (2) ZA200306599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US7601842B2 (en) 2003-02-18 2009-10-13 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
BRPI0407954A (pt) * 2003-03-17 2006-03-07 Kaneka Corp processo para a produção de derivado de amida de ácido (r)-3-[4-(trifluorometil) fenilamino]-pentanóico
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
BRPI0414186A (pt) * 2003-10-08 2006-10-31 Lilly Co Eli compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ,インコーポレイテッド Hdlを高める併用療法用複合物
AR048528A1 (es) * 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
CA2570688A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
AU2006216713A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
AU2012243583B2 (en) 2011-04-12 2015-10-22 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
PL2729142T3 (pl) * 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
CN105143193B (zh) 2013-01-31 2017-12-15 株式会社钟根堂 作为cetp抑制剂的联芳基或杂环联芳基取代的环己烯衍生化合物
HK1221073A1 (zh) * 2013-11-11 2017-05-19 Lonza Ltd 利用路易斯酸制备第13族元素的氰基化合物的方法
LT3180314T (lt) * 2014-08-12 2022-11-10 Newamsterdam Pharma B.V. Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205037B (de) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
ES2257864T3 (es) 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
RU2003131870A (ru) 2005-01-27
YU84403A (sh) 2006-08-17
KR100591998B1 (ko) 2006-06-22
DK1425270T3 (da) 2006-07-03
HU225777B1 (en) 2007-08-28
YU84303A (sh) 2006-05-25
ATE316957T1 (de) 2006-02-15
DK1383734T3 (da) 2006-05-15
US20030216576A1 (en) 2003-11-20
EP1425270B1 (de) 2006-03-29
HUP0304041A2 (hu) 2004-04-28
KR20040015200A (ko) 2004-02-18
AU2002253448B2 (en) 2007-07-05
EP1425270A2 (de) 2004-06-09
JP3924250B2 (ja) 2007-06-06
IL157546A0 (en) 2004-03-28
WO2002088069A2 (en) 2002-11-07
DE60209004D1 (de) 2006-04-13
WO2002088069A9 (en) 2003-12-04
BR0209291A (pt) 2004-07-13
DE60210265T2 (de) 2006-10-12
WO2002088069A3 (en) 2003-02-20
EP1383734B1 (de) 2006-02-01
CN1529696A (zh) 2004-09-15
CZ20032898A3 (cs) 2004-07-14
US6689897B2 (en) 2004-02-10
RU2003131871A (ru) 2005-04-10
HUP0304041A3 (en) 2005-08-29
JP2004527556A (ja) 2004-09-09
CN1297541C (zh) 2007-01-31
WO2002088085A3 (en) 2004-03-25
EP1383734A2 (de) 2004-01-28
TWI250974B (en) 2006-03-11
IL157544A0 (en) 2004-03-28
PL366584A1 (en) 2005-02-07
ZA200306600B (en) 2004-08-25
US20030073843A1 (en) 2003-04-17
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
JP2004531541A (ja) 2004-10-14
PT1425270E (pt) 2006-07-31
CA2445693A1 (en) 2002-11-07
HK1062294A1 (en) 2004-10-29
CN1680292A (zh) 2005-10-12
US20020177716A1 (en) 2002-11-28
PL366700A1 (en) 2005-02-07
MXPA03009936A (es) 2004-01-29
HUP0304039A2 (hu) 2004-03-29
ES2256461T3 (es) 2006-07-16
CA2445623A1 (en) 2002-11-07
WO2002088085A2 (en) 2002-11-07
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
RU2265010C2 (ru) 2005-11-27
AR035963A1 (es) 2004-07-28
CN1267411C (zh) 2006-08-02
DE60209004T2 (de) 2006-09-28
MXPA03009935A (es) 2004-01-29
CZ20032900A3 (cs) 2004-06-16
ES2259080T3 (es) 2006-09-16
JP3924251B2 (ja) 2007-06-06
KR100639745B1 (ko) 2006-10-30
CN1505609A (zh) 2004-06-16
DE60210265D1 (de) 2006-05-18
AR044706A2 (es) 2005-09-21
CN100357265C (zh) 2007-12-26
US6600045B2 (en) 2003-07-29
US6706881B2 (en) 2004-03-16
HUP0304039A3 (en) 2005-10-28
ZA200306599B (en) 2004-10-22

Similar Documents

Publication Publication Date Title
ATE321755T1 (de) Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
DE60233267D1 (de) Vorrichtung und Verfahren zur Herstellung von Metallschichten
DE60212811D1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle und so hergestellte mineralwolleprodukte
ATE302191T1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE50006193D1 (de) Verfahren zur herstellung von otoplastiken und otoplastik
DE60238919D1 (de) System und verfahren zur überwachung und vermeidung von kollisionen
DE122007000077I2 (de) Verfahren zur herstellung von substituierten octanoyl-amiden
DE60135686D1 (de) Vorrichtung und Verfahren zur Personenidentifizierung
ATE403641T1 (de) Verfahren zur herstellung von o- desmethylvenlafaxin
DE60214946D1 (de) Verfahren und System zur Bereitstellung von Informationen
DE50006246D1 (de) Verfahren und vorrichtung zur herstellung von borstenwaren und danach hergestellte borstenwaren
DE60138099D1 (de) Verfahren zur herstellung von substituierten octanoyl-amiden
ATE362707T1 (de) Verfahren zur herstellung von milchpulver und konzentrierten milchprodukten
ATE382631T1 (de) Verfahren zur herstellung von virusinaktiviertem humanem gammaglobulin g
DE60225539D1 (de) Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE50010110D1 (de) Verfahren zur herstellung von plattenförmigen produkten
DE60230908D1 (de) Verfahren zur herstellung von polyarylenethern
DE60216756D1 (de) Verfahren zur herstellung von hochdichten produkten aus rostfreiem stahl
ATE286011T1 (de) Verfahren zur herstellung von 1-octen
EP1641581A4 (de) Verfahren und vorrichtung zur herstellung von metallverbindungen
DE60213444D1 (de) Fluorpolymerlaminate und verfahren zur herstellung derselben
DE60135240D1 (de) Verfahren und zwischenprodukte zur herstellung 7-substitiuerter antiestrogene
DE60214560D1 (de) Verfahren und vorrichtung zur herstellung von faserformkörpern
DE60026765D1 (de) Vorrichtung und Verfahren zur Herstellung von Etiketten
ATE316959T1 (de) Verfahren zur herstellung von 2- halogenpyridincarbonsäureamiden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425270

Country of ref document: EP

REN Ceased due to non-payment of the annual fee